Heart failure & cardiomyopathiesGuideline or statement
Patient Phenotype Profiling in Heart Failure with Preserved Ejection Fraction to Guide Therapeutic Decision Making. A Scientific Statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension
- Scientific statement
Recommendations
As issued by the authors
SGLT2 inhibitors in all patients with heart failure with preserved ejection fraction (HFpEF), plus therapy tailored to each patient's clinical profile
An algorithm to identify the most common HFpEF phenotypes and the evidence-based treatment strategy for each, taking into account multiple comorbidities and polypharmacy
Original publication
Patient Phenotype Profiling in Heart Failure with Preserved Ejection Fraction to Guide Therapeutic Decision Making. A Scientific Statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension. Eur J Heart Fail. Published 17 July 2023. doi:10.1002/ejhf.2894
Summarised from the published abstract; every number is checked against it